The Indiana CTSI Disease and Therapeutic Response Modeling Program uses quantitative models of disease and drug effect/exposure to speed new therapies from the lab into new patient therapies.
Disease and therapeutic response modeling plays a signific personalized medicine through the use of biomarkers that can predict disease severity and/or therapeutic response, as well as pharmacogenomics to target genetically identifiable response populations.
This program involves a full partnership and significant resources from Eli Lilly and Co., a world-leader in pharmacokinetic/pharmacodynamic driven drug development and in applying these models to human disease.
- Provide substantial salary support to six new post-doctoral level training positions within the Indiana CTSI under a master agreement with Eli Lilly.
- Increase the capability of disease-state and disease progression modeling by training individuals in specific competencies.
- Develop major disease state and disease progression models and makes these models publically available through the CTSA Consortium